News Headline Summary

Johnson & Johnson (JNJ) failed to warn vaginal mesh risk, lawyer tells jury

- First case of 1,800 in vaginal mesh trial.

Reaction details (11:24)

- No immediate reaction in JNJ shares, last trade at USD 72.70 (+0.66%).

Analysis details (11:25)

- The trial relates to a vaginal mesh implant in a case brought by a South Dakota woman who blames the product for constant pain and 18 subsequent operations.

10 Jan 2013 - 11:22 - Equities - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: